Verastem pairs a perfect 4-quarter earnings beat streak and positive insider signals with real technical risk, an RSI of 92 inside a still-confirmed downtrend and 28% short interest the engine calls justified, leaving the position at zero conviction ahead of an earnings catalyst in 19 days.
Thesis pillars
- Perfect Earnings Beat Streak Catalyst→Stable
- Positive Insider Activity Bull Case→Stable
- Overbought Bear Rally Risk↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Verastem, Inc. (VSTM) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $6.30, but acceptable to hold if already in. Reasons: Concentration risk — Product: AVMAPKI FAKZYNJA CO-PACK; Leverage penalty (D/E 1.0): -0.5.
Verastem is a commercial-stage biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, marketing AVMAPKI FAKZYNJA CO-PACK (avutometinib plus defactinib) as the first FDA-approved treatment for KRAS-mutated recurrent low-grade serous ovarian cancer following... Read more
Hold if already holding. Not a fresh buy at $6.30, but acceptable to hold if already in. Reasons: Concentration risk — Product: AVMAPKI FAKZYNJA CO-PACK; Leverage penalty (D/E 1.0): -0.5. Chart setup: Death cross but MACD improving, RSI 74. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.3/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Verastem, Inc.
About Verastem, Inc.
Verastem's AVMAPKI FAKZYNJA CO-PACK, the first FDA-approved treatment for KRAS-mutated recurrent low-grade serous ovarian cancer, received accelerated approval on May 8, 2025 and generated $30.9 million in net product revenue during its first seven months of commercial launch. The combination therapy is only commercially available in the United States, where an estimated 6,000 to 8,000 women live with LGSOC, and roughly 30% carry a KRAS mutation.
AVMAPKI FAKZYNJA CO-PACK reaches patients through designated specialty pharmacies and distributors, with the product available within five days of approval through two specialty pharmacies onboarded in the second quarter of 2025 and four specialty distributors added in the third quarter; the company estimates the top 100 commercial healthcare organizations in the U.S. represent approximately 50% of the sales opportunity for the drug. Verastem licensed its KRAS G12D inhibitor VS-7375 from GenFleet Therapeutics in January 2025, with GenFleet separately developing the same molecule as GFH375 in China under its own trials. A September 2021 clinical collaboration with Amgen to combine avutometinib with Amgen's LUMAKRAS was discontinued in December 2025 so the company could redirect resources toward VS-7375. Verastem competes against numerous large pharmaceutical and biotechnology companies pursuing RAS/MAPK pathway therapies, including AbbVie and AstraZeneca.
Show full overview
Verastem's business rests on a single approved product still under conditional authorization: the 10-K states the company is highly dependent on the commercial success of AVMAPKI FAKZYNJA CO-PACK for the foreseeable future, and because the drug holds accelerated rather than full approval, continued marketing depends on confirming clinical benefit in the ongoing Phase 3 RAMP 301 trial, with a topline progression-free-survival readout not expected until mid-2027. Enrollment finished a quarter ahead of schedule in October 2025, but a negative or inconclusive result at that 2027 readout could jeopardize the product's continued approval, not just future label expansion.
See also: Healthcare · Biotechnology
From Verastem, Inc.'s most recent 10-K filing, extracted July 19, 2026.
Recent developments
updated 2026-07-27Recent Developments — Verastem, Inc.
Latest news
- NEWS 12 Health Care Stocks Moving In Thursday's After-Market Session — benzinga Jul 23, 2026 neutral
- NEWS Verastem Oncology Doses First Patient In Phase 2 Trial Of VS-7375 For KRAS G12D-Mutated Advanced Non-Small Cell Lung Can — benzinga Jul 22, 2026 positive
- NEWS These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why — benzinga Jul 21, 2026 positive
- NEWS RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14 — benzinga Jul 7, 2026 positive
Generated 2026-07-28T05:42:44Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductAVMAPKI FAKZYNJA CO-PACK10-K Item 1A: 'We are highly dependent on the commercial success of AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the U.S for the foreseeable future.'
- MEDIUMCustomertop 100 commercial healthcare organizations50%10-K Item 1: 'the top 100 commercial healthcare organizations in the U.S. comprise approximately 50% of the sales opportunity'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $6.30, but acceptable to hold if already in. Reasons: Concentration risk — Product: AVMAPKI FAKZYNJA CO-PACK; Leverage penalty (D/E 1.0): -0.5. Chart setup: Death cross but MACD improving, RSI 74. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $13.05 (+107.1%), stop $5.65 (−11.5%), A.R:R 7.6:1. Score 5.3/10, moderate confidence.
Take-profit target: $13.05 (+114.6% upside). Target $13.05 (+107.1%), stop $5.65 (−11.5%), A.R:R 7.6:1. Stop-loss: $5.65.
Concentration risk — Product: AVMAPKI FAKZYNJA CO-PACK; Leverage penalty (D/E 1.0): -0.5; Below 200-MA, MA slope -9.3%/30d (confirmed downtrend).
Verastem, Inc. trades at a P/E of N/A (forward -5.2). TrendMatrix value score: 6.6/10. Verdict: Hold.
15 analysts cover VSTM with a consensus score of 4.3/5. Average price target: $15.
What does Verastem, Inc. do?Verastem is a commercial-stage biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, marketing AVMAPKI...
Verastem is a commercial-stage biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, marketing AVMAPKI FAKZYNJA CO-PACK (avutometinib plus defactinib) as the first FDA-approved treatment for KRAS-mutated recurrent low-grade serous ovarian cancer following accelerated approval on May 8, 2025. The product generated $30.9 million in net product revenue during its first seven months of commercial launch in 2025, while the company advances VS-7375, a KRAS G12D inhibitor licensed from GenFleet Therapeutics in January 2025, through Phase 1/2 trials.